Relationship between a uterine fibroid diagnosis and the risk of adverse obstetrical outcomes: a cohort study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
17 02 2020
Historique:
entrez: 20 2 2020
pubmed: 20 2 2020
medline: 16 2 2021
Statut: epublish

Résumé

The aim was to investigate the association between clinically significant uterine fibroids and preterm birth, caesarean section (CS), postpartum haemorrhage (PPH), placental abruption, intrauterine growth restriction (IUGR) and uterine rupture. A historical cohort study based on data from the Danish National Birth Cohort, the Danish National Patient Registry and the Danish National Birth Registry (DNBR). The final study population consisted of 92 696 pregnancies and was divided into four groups for comparison. Group 1: pregnancies of women without a fibroid diagnosis code or fibroid operation code; group 2: pregnancies of women with a fibroid diagnosis code before pregnancy, during pregnancy or up to 1 year after delivery, and no fibroid operation code before pregnancy; group 3: pregnancies of women with a fibroid diagnosis code given more than 1 year after delivery; and group 4: pregnancies of women with a fibroid operation code given before pregnancy. A diagnosis of fibroids before pregnancy yielded an increased risk of preterm birth (gestational age (GA) ≤37 weeks) (OR 2.27 (1.30─3.96)) and extreme preterm birth (GA 22+0─27+6 weeks, OR 20.09 (8.04─50.22)). The risk of CS was increased (OR 1.83 (1.23─2.72)) for women with a fibroid diagnosis code given before pregnancy; significantly increased risk of elective CS (OR 1.92 (1.11─3.32)), but not acute CS (OR 1.54 (0.94─2.52)). The risks of PPH, placental abruption or IUGR were not increased in any of the groups. We found a strong association between clinically significant uterine fibroids and preterm birth, and an association between clinically significant uterine fibroids and CS. In contrast, no association between clinically significant uterine fibroids and PPH, placental abruption or IUGR was seen.

Identifiants

pubmed: 32071172
pii: bmjopen-2019-032104
doi: 10.1136/bmjopen-2019-032104
pmc: PMC7044982
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e032104

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Am J Obstet Gynecol. 1989 May;160(5 Pt 1):1212-6
pubmed: 2658611
Epidemiology. 2006 Jul;17(4):413-8
pubmed: 16755269
J Matern Fetal Neonatal Med. 2012 Jun;25(6):710-3
pubmed: 22409539
Obstet Gynecol Sci. 2013 Nov;56(6):375-81
pubmed: 24396816
J Minim Invasive Gynecol. 2012 Nov-Dec;19(6):762-7
pubmed: 23084683
J Obstet Gynaecol Res. 2017 Dec;43(12):1789-1804
pubmed: 28892210
Obstet Gynecol Clin North Am. 2006 Mar;33(1):153-69
pubmed: 16504813
Eur J Epidemiol. 2010 May;25(5):349-55
pubmed: 20349116
Scand J Public Health. 2001 Dec;29(4):300-7
pubmed: 11775787
Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:74-84
pubmed: 26723475
Am J Obstet Gynecol. 2003 Jan;188(1):100-7
pubmed: 12548202
Ugeskr Laeger. 2009 Feb 2;171(6):412-5
pubmed: 19208329
Fertil Steril. 2009 Apr;91(4):1215-23
pubmed: 18339376
Acta Obstet Gynecol Scand. 2018 Apr;97(4):417-423
pubmed: 29453880
J Perinat Med. 1978;6(3):165-8
pubmed: 702266
J Matern Fetal Neonatal Med. 2015 Mar;28(4):484-8
pubmed: 24803127
Obstet Gynecol. 2009 Mar;113(3):630-5
pubmed: 19300327
Obstet Gynecol. 1988 Dec;72(6):853-7
pubmed: 3186092
Epidemiology. 2011 Sep;22(5):745
pubmed: 21811114
Am J Perinatol. 2016 Oct;33(12):1218-22
pubmed: 27631601
BMC Pregnancy Childbirth. 2017 Jan 10;17(1):17
pubmed: 28068990
Semin Reprod Med. 2010 May;28(3):218-27
pubmed: 20414844
Clin Exp Obstet Gynecol. 2016;43(6):844-848
pubmed: 29944235
Minerva Ginecol. 2010 Jun;62(3):225-36
pubmed: 20595947
Biomed Res Int. 2018 Mar 26;2018:8367068
pubmed: 30151390
Am J Obstet Gynecol. 2014 Oct;211(4):395.e1-5
pubmed: 24705132
Fertil Steril. 2012 Jan;97(1):107-10
pubmed: 22100166
Am J Clin Nutr. 1996 Oct;64(4):650-8
pubmed: 8839517
Clin Obstet Gynecol. 2016 Mar;59(1):119-27
pubmed: 26670833
Obstet Gynecol. 2000 May;95(5):764-9
pubmed: 10775744
J Matern Fetal Neonatal Med. 2016 Nov;29(21):3454-60
pubmed: 26653679
Am J Obstet Gynecol. 2008 Apr;198(4):357-66
pubmed: 18395031

Auteurs

Kamilla Karlsen (K)

Gynecology and Obstetrics, Clinical Institute University of Southern Denmark, Odense, Denmark kamilla.karlsen@rsyd.dk.

Ulrik Schiøler Kesmodel (U)

Research Unit of Gynecology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Department of Clinical Medicine, Aalborg Universitet, Aalborg, Denmark.

Ole Mogensen (O)

Department of Gynecology, Aarhus University Hospital and Faculty of Health, Aarhus University, Aarhus, Denmark.

Peter Humaidan (P)

Skive Regional Hospital, The Fertility Clinic, Skive, Denmark.
Faculty of Health, Aarhus Universitet, Aarhus, Denmark.

Pernille Ravn (P)

Clinical Institute, Syddansk Universitet, Odense, Denmark.
Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH